Colon capsule developer Check-Cap said that interim results from an ongoing multicenter clinical investigation of version 3 of its C-Scan system showed promising results for polyp detection.
In a study of 31 patients with unprepped colons, C-Scan version 3 yielded 76% sensitivity and 80% specificity for polyp detection, according to the company. The new version of C-Scan features better scan imaging density, 2D/3D imaging, and a new motility analysis algorithm that was recently tested on two years of continued clinical study data, Check-Cap said.
Final results from the study are scheduled for release in the second quarter of 2019 and will include a more substantial number of patients. Meanwhile, Check-Cap said it is working on establishing a manufacturing line with GE Healthcare and launching a pilot trial in the U.S. in the fourth quarter of 2018.
